A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations
Maria Reviejo, Nazaret Hortelano-Hernandez, Raul E Tizado, Oscar Briz, Jose J G Marin · 2026
Read A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations by Maria Reviejo, Nazaret Hortelano-Hernandez, Raul E Tizado, Oscar Briz, Jose J G Marin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13350699.txt.
Description
Maria Reviejo and co-authors reviewed a five-gene signature meant to predict response to the liver cancer drug sorafenib in a 2026 article. Liver cancer is usually found late, in livers already scarred, when surgery and transplant are off the table and drug therapy carries the load.
Gene activity patterns in tumour tissue are proposed to sort likely responders before treatment begins. The authors weigh the signature's promise against its limits, including how well findings from study cohorts survive contact with varied real patients. A working predictor would spare non-responders months of side effects and push them sooner toward better options.
Catalog record
| CREATOR | Maria Reviejo, Nazaret Hortelano-Hernandez, Raul E Tizado, Oscar Briz, Jose J G Marin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20165 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |